Prucalopride (Resolor) has been recommended by NICE as a possible treatment for women with chronic constipation.
According to the new guidance, women are eligible to receive the 5HT4 agonist on the NHS if:
- they have tried at least two different types of laxatives at the highest tolerated recommended doses for at least 6 months, without adequate relief
- invasive treatment of constipation is being considered.
Prucalopride should be prescribed only by a clinician experienced in treating chronic constipation, who has carefully reviewed the woman’s previous laxative use. Treatment should be reviewed after 4 weeks.
Prucalopride was launched in January 2010. Marketing authorisation was granted for use only in women as regulators felt that the drug had not been sufficiently evaluated in men.
Further information: Movetis